Microbiotica ’s Post

🚀 Diving into Novartis's Q2 2024 Performance: Episode 4, Season 2 of our Pipeline Analysis series! Key Highlights 💼 Financial Strength: 📈 Net Revenue: $24.3 billion 🔬 R&D Investment: $2.3 billion 🏆Top 5 Revenue Generators: Entresto®, Kesimpta®,Cosentyx®,Kisqali®and Pluvicto®spanning in critical therapeutic areas CVRM, Immunology, and Oncology 🧪Pipeline Advancements: Atrasentan (IgAN): US FDA submission Scemblix® (CML 1L): US submission, Breakthrough Therapy Designation Lutathera® (GEP-NET 1L G2/G3): EU submission #PharmaceuticalIndustry #Novartis #Q2Performance #PipelineAnalysis Follow RAS LifeScience Solutions for more in-depth insights and updates on the pharmaceutical landscape!

Follow RAS LifeScience Solutions for more in-depth insights and updates on the pharmaceutical landscape!

Next week JJP Biologics CSO, Dr. Louis Boon, will present on Tuesday afternoon October 15th at the Festival of Biologics in Basel in the precision medicine stream. Louis Boon will touch upon JJP Biologics unique discovery strategy to select a potential biomarker/companion diagnostic prior to target selection. As a consequence JJP Biologics does not work on targets for which on forehand no biomarker could be envisioned. The JJP-1212 selection strategy will be used to exemplify this strategy. The clinical observation is, that in almost every autoimmune and fibrotic disease, a subgroup of patients exists with high IgA autoantibodies that suffer from more severe disease and are less responsive to current available treatments. Since for all of those indications, disease-specific autoantigens are known, the levels of IgA autoantibodies can easily be determined as a potential stratification tool used already in early clinical studies. This will decrease the size and thus costs of such studies and will increase the potential of clinical success. Louis Boon will take you along the journey of JJP-1212. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #SMARTGOOSE

This week's top #pharma news stories...https://lnkd.in/e4ssBdcG 1. Roche highlights new deals, big plans in obesity, #breastcancer 2. Roche further reignites hope as Kezar stumbles in rugged #lupus terrain 3. Rivus Pharmaceuticalsgets to heart of #obesity drug shortfalls with mid-stage data drop 4. Eli Lilly and Company catches up on Mounjaro and Zepbound, commits $4.5B to novel facility 5. Chart of the week: Taking stock as the third quarter closes #biotechnology #cancer #clinicalresearch #clinicaltrials #drugdevelopment #EMA #FDA #medicalaffairs #mergersandacquisitions #obesity #oncology #pharmaceuticals #regulatoryaffairs

St. Louis-based API Innovation Center (APIIC) has developed a reliable and efficient source for the active ingredients used in the cancer treatment drug lomustine. In partnership with Apertus Pharmaceuticals, also based in the state of Missouri, the APIIC will use its manufacturing technology to accelerate the production of the medication, which medical and political figures alike have pushed amid pharma supply chain issues caused by the COVID-19 pandemic. Lomustine, also known as CCNU, is a chemotherapy drug typically used to treat brain tumors. The collaboration, which also includes the Glioblastoma Foundation, focuses on bringing the production of the medication onto U.S. soil in an effort to reduce costs and ensure sustained availability. Missouri state leaders hope the project will enhance national health security and position Missouri as a hub for essential pharmaceutical manufacturing. Last year, the APIIC was awarded $9.5 million from the Missouri Technology Corporations Advanced Manufacturing Residency Grant Program and will reportedly invest the funds in the construction of a regional hub for advanced drug manufacturing. #SeniorLiving #OlderAdults #Cancer #HealthCare #InTheNews

Let's Talk About Biosimilars with Qualite Pharma Biosimilars are revolutionising the healthcare landscape, offering cost-effective alternatives to biologic therapies without compromising on quality or efficacy. At Qualite Pharma, we're passionate about driving conversations around biosimilars and their immense potential to enhance patient access to life-saving treatments. Biosimilars play a pivotal role in expanding access to essential treatments for a wide range of medical conditions, from autoimmune disorders to cancer. By offering comparable efficacy and safety profiles to their reference biologics, biosimilars empower patients to receive high-quality care while mitigating healthcare costs. Through rigorous research, development, and adherence to regulatory guidelines, we ensure that patients and healthcare providers can trust in the reliability and effectiveness of our offerings. Join Qualite Pharma in championing biosimilars as a catalyst for positive change in healthcare. #QualitePharma #Biosimilars #HealthcareInnovation #AccessToMedicine #LetsTalkBiosimilars

https://buff.ly/3VsgMLb 𝐅𝐃𝐀'𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐖𝐚𝐫𝐩 𝐒𝐩𝐞𝐞𝐝 2.0: 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 🚀🔬 💠 The FDA is taking a page from Operation Warp Speed with its new pilot program, START, designed to accelerate the development of rare disease therapies. This initiative brings together the FDA and seven leading biotech companies to streamline the approval process and bring much-needed treatments to patients faster. 💠 By fostering close collaboration between regulators and drug developers, START aims to optimize clinical trial design, refine patient selection, and enhance communication throughout the development process. 💠 Companies like Denali Therapeutics, Larimar Therapeutics, Grace Science, Neurogene, and Myrtelle are already participating in the program, working on groundbreaking therapies for a variety of rare conditions. 💠 I see this as a much-needed step in the right direction to help sponsors deal with the difficulties in drug development in this area as a result of small patient populations, lack of established endpoints, and the complexities of patient recruitment and retention. #FDA #RareDisease #Biotech #Innovation #DrugDevelopment #orphandrugs

🔊 BLENREP- Second Phase III Win? Blenrep Success in Phase III Trials: GSK's Blenrep, initially withdrawn from the U.S. market, achieved positive results in two recent Phase III trials for multiple myeloma. DREAMM-7 and DREAMM-8 trials demonstrated significant extension of progression-free survival and a positive trend in overall survival compared to standard care. Regulatory Path and Market Impact: GSK plans to discuss successful trial data with regulators, potentially leading to a filing for Blenrep's reintroduction to the U.S. market. If successful, Blenrep could reshape the multiple myeloma treatment landscape and positively impact GSK's sales, exceeding current forecasts. Competition and Future Outlook: Blenrep may face competition from existing BCMA-directed therapies in the market. Successful reintroduction could enable GSK to surpass mid-term sales targets and enhance its position in the evolving oncology landscape. #lifesciences #biotech #fda

Eribulin is a novel non-taxane chemotherapeutic agent used for the treatment of locally advanced or metastatic breast cancer patients. Enhance your drug development and analysis with 𝐏𝐡𝐚𝐫𝐦𝐚𝐟𝐟𝐢𝐥𝐢𝐚𝐭𝐞𝐬’ 𝐥𝐚𝐭𝐞𝐬𝐭 𝐡𝐢𝐠𝐡 𝐪𝐮𝐚𝐥𝐢𝐭𝐲 Eribulin 𝐫𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬, 𝐢𝐦𝐩𝐮𝐫𝐢𝐭𝐢𝐞𝐬 & 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐬. 𝐓𝐨 𝐯𝐢𝐞𝐰 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐥𝐢𝐬𝐭 𝐨𝐟 𝐄𝐫𝐢𝐛𝐮𝐥𝐢𝐧 𝐈𝐦𝐩𝐮𝐫𝐢𝐭𝐢𝐞𝐬, 𝐀𝐏𝐈 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 & 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐬. 𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 - https://lnkd.in/gf4wZ6Qn To view full scientific literature & gear up your knowledge on NOVEL Eribulin, click here - https://lnkd.in/gvtQ83JF #research #ReferenceStandards #Pharmaffiliates #AnalyticalChemistry #DrugDiscovery #Impurities #contractresearch #cro #cdmo #stableisotopes #intermediates #pharmaceutical #research #researchanddevelopment #analyticalchemistry #drugdevelopment #qualitycontrol #qc #drugdiscovery #pharmacokinetics #CMC #impurityqualification #Pharmacodynamics #drugmanufacturing #healthcareinnovation #pharmamanufacturing #api #activepharmaceuticalingredient #Eribulin

▶️🖱️ Now available on-demand! Watch our webinar featured on Scientist.com on the Applications of Humanized Mice in the Evaluation of Antibody-Drug Conjugates to Treat Autoimmune Diseases! 👉 Click here to watch: https://buff.ly/3yGYTiT This webinar features our Director of Scientific Engagement, Dr. Jun Wang, and BioRay Pharmaceutical's President, Dr. Gang Chen. Key topics include: ☑️ Advantages of using humanized mouse models to evaluate ADCs ☑️ Applications of humanized mice to evaluate ADCs in autoimmune disease models ☑️ The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADCTM) #adcs #antibodydrugconjugates #autoimmune #mousemodels https://buff.ly/3yGYTiT